Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 7.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 279,682 shares of the company’s stock after purchasing an additional 19,562 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.69% of Keros Therapeutics worth $4,427,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of KROS. Exchange Traded Concepts LLC acquired a new position in shares of Keros Therapeutics during the 4th quarter valued at $99,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company’s stock worth $136,000 after purchasing an additional 1,372 shares in the last quarter. Handelsbanken Fonder AB lifted its stake in shares of Keros Therapeutics by 11.3% during the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company’s stock worth $171,000 after purchasing an additional 1,100 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter worth about $216,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Keros Therapeutics by 36.7% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares in the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

Keros Therapeutics Stock Down 1.3 %

Shares of Keros Therapeutics stock opened at $11.29 on Wednesday. The business has a 50-day moving average price of $11.13 and a 200 day moving average price of $35.22. Keros Therapeutics, Inc. has a fifty-two week low of $9.78 and a fifty-two week high of $72.37. The firm has a market cap of $457.94 million, a P/E ratio of -2.17 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on KROS shares. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 12th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Truist Financial cut their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, December 23rd. HC Wainwright lowered their target price on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Finally, Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $47.00 to $15.00 in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.